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Abstract. Our previous study demonstrated that inhibition 
of erythropoietin-producing hepatoma cell line-B2 (EphB2) 
expression resulted in the promotion of cancer growth, with 
EphB2 acting as a tumor suppressor in pancreatic cancer. 
Qingyihuaji formula (QYHJ), a traditional Chinese medicine, 
acts as an independent protective factor for pancreatic cancer 
patient survival and different patients have shown various 
responses to QYHJ treatment. In the current study, the different 
effects on tumor growth inhibition following QYHJ treatment 
in cells with different levels of EphB2 expression were investi-
gated to reveal the mechanism. A subcutaneously transplanted 
tumor model using cancer cells with different levels of EphB2 
expression were established in vivo and received a four-week 
QYHJ intervention. Tumor weight inhibitory rate and tumor 
volume deflation were evaluated. The cell cycle and apoptosis 
were analyzed by flow cytometry, and reverse transcription 
polymerase chain reaction and western blot analysis were used 
to assess mRNA and protein levels. The results showed that the 
tumor weight inhibitory rate was 31.40, 31.33 and 18.36% in 
CFPAC-1, CFPAC-1 control RNAi and CFPAC-1 EphB2 RNAi 
cells following QYHJ treatment, respectively. A statistically 
significant difference was identified in CFPAC‑1 (P<0.05) and 
CFPAC-1 control RNAi (P<0.01) cells. In addition, a statisti-
cally significant increase was identified in the G0/G1 phase 
population (P<0.05) and a statistically significant decrease 
was identified in the S phase population (P<0.05) in CFPAC‑1 
and CFPAC-1 control RNAi cells; however, no significant 
difference was identified in the CFPAC‑1 EphB2 RNAi cells 
following QYHJ treatment. QYHJ upregulated the mRNA and 
protein level of Eph receptor-interacting B1 (EphrinB1) in the 
cells that were expressing different levels of EphB2, however, 
QYHJ did not regulate EphB2 expression. In CFPAC-1 and 
CFPAC-1 control RNAi cells, the QYHJ treatment resulted 
in a statistically significant decrease in cyclin-dependent 
kinase 6 (CDK6) mRNA (P<0.05) and protein (P<0.05) levels. 
The high expression of EphB2 predicted the superior response 
rate to the QYHJ treatment through a mechanism of inhibiting 
the cell cycle by an EphrinB1-EphB2-induced CDK6 decrease 
in CFPAC-1 cells. Therefore, EphB2 acts as a predictive factor 
for QYHJ treatment in pancreatic cancer CFPAC-1 cells.
Introduction
Pancreatic cancer is a highly lethal disease and tumors are 
often late stage at diagnosis, at which point there are few effec-
tive treatment options. In 2012, pancreatic cancer resulted in 
~85.13% of cancer‑related mortality within the United States, 
the five‑year survival rate was ≤5% and the median survival 
was less than six months (1). Notable improvements have been 
made in the five‑year survival rates for a number of cancers over 
the past 30 years, with the exception of pancreatic cancer (1,2). 
Therefore, it is imperative to identify novel treatment strate-
gies to prolong patient survival time for pancreatic cancer. 
Qingyihuaji formula (QYHJ) has been used in pancreatic 
cancer treatment for a number of years at the Fudan University 
Cancer Center (Shanghai, China). Our previous retrospective 
studies have shown that QYHJ treatment prolongs the survival 
time of pancreatic cancer patients, with multivariate analysis 
demonstrating that QYHJ acted as an independent protec-
tive factor for pancreatic cancer with liver metastases (3‑5). 
However, QYHJ appeared to prolong the survival time for one 
subgroup of patients, however, was ineffective for a different 
group of patients. Our previous study showed that different 
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pancreatic cancer cell lines with different levels of erythro-
poietin-producing hepatoma cell line-B2 (EphB2) expression 
exhibited different responses to QYHJ treatment (6). It has 
previously been confirmed that EphB2 is a prognostic factor 
for several types of cancer and acts preferentially as a tumor 
suppressor in various cancers (7‑15). Furthermore, our 
previous study revealed that inhibition of EphB2 expression in 
pancreatic cancer CFPAC-1 cells resulted in the promotion of 
cancer growth by stimulating cell proliferation and decreasing 
apoptosis. Therefore, EphB2 acts as a tumor suppressor in 
pancreatic cancer (16). Traditional Chinese medicine (TCM) 
is regarded as a multi-target therapy, which is similar to target 
therapy in modern medicine (17,18). Previous studies revealed 
that not all patients benefit from target therapies as patients 
may have their own effective population according to their 
distinctive predictors. Thus, the aim of the present study was 
to investigate the correlation between the different levels of 
EphB2 expression and the response to QYHJ treatment. In 
addition, to elucidate whether EphB2 acts as a predictive 
factor for QYHJ treatment.
Materials and methods
Cell cultures. In 1990, the human pancreatic cancer CFPAC-1 
cell line was established from a patient with cystic fibrosis by 
Schoumacher et al (19). CFPAC-1 EphB2 RNAi and CFPAC-1 
control RNAi cells were transfected by lentivirus-based 
RNAi to inhibit EphB2 expression, and served as a control 
RNAi in our previous study (16). Cells were cultured in 
RPMI-1640 medium (Gibco‑BRL, Carlsbad, CA, USA) with 
10% heat‑inactivated fetal bovine serum (Hyclone, Logan, UT, 
USA) under a 5% CO2 atmosphere at 37˚C. The medium was 
changed at 24 h intervals when the culture had almost reached 
confluence.
Drug preparation and intervention. QYHJ is composed 
of  Hedyot id is  herba ,  A morphopha l lus  konjac, 
Herba scutelleriae barbatae, coix seed, akebia stem, 
Gynostemma pentaphyllum and java amomum fruit. The herb 
powder was produced by Jiangyin Tianjiang Pharmaceutical 
Co., Ltd., (Jiangyin, China). QYHJ was prepared by dissolving 
the herb powder into distilled water to the required concentra-
tion. The daily dosage of QYHJ for the nude mice was calculated 
according to the following human-mouse transfer formula: 
Db = Da x (Rb/Ra) x 2/3 (Wb/Wa) where D, R, and W represent 
dosage, weight coefficient and body weight, respectively, and 
a and b represent human and mouse, respectively. The QYHJ 
group received a total of 200 µl liquid QYHJ twice a day by oral 
gavage as well as a 36 g/kg daily dosage, the gemcitabine group 
received an intraperitoneal injection of 120 mg/kg gemcitabine 
on days one, eight and 15 and the control group received an oral 
gavage of a total of 200 µl normal saline twice a day. All of the 
animal studies were reviewed and approved by the Animal Care 
and Use Committee of Fudan University (Shanghai, China) and 
were in accordance with the guidelines of the Department of 
Health and Human Services.
Assessment of tumorigenicity in vivo. In total, 1x106 CFPAC-1, 
CFPAC-1 control RNAi and CFPAC-1 EphB2 RNAi cells 
(200 µl) with different levels of EphB2 expression were 
injected subcutaneously into the right flank of eight‑week‑old 
female BALB/c nude mice. Tumor volume was measured 
twice per week and calculated using the following formula: 
Tumor volume = 0.52 x A x B2, where A is the length (long 
diameter) and B is the width (short diameter) of the tumor. 
Following four weeks of intervention with drugs, the mice 
were sacrificed, the tumors were dissected and the tumor 
weight was measured. The tumor weight inhibitory rate was 
calculated according to the following formula: Tumor weight 
inhibitory rate = 100 x (tumor weight of control group - tumor 
weight of QYHJ group) / tumor weight of control group.
Cell cycle and apoptosis analyses. The tumors were dissected, 
ground, centrifuged and washed with phosphate-buffered 
saline (PBS). Next, 1x106 cells were fixed in 1 ml ethanol at 
4˚C for 1 h. Following centrifugation at 1,500 x g for 10 min 
(L‑550, Changsha Xiangyi Centrifuge Instrument Co., Ltd., 
Changsha, China) and washing with PBS, the cells were 
resuspended in 250 µl PBS containing 12.5 µg RNase and 
incubated for 30 min at 37˚C. Cellular DNA was stained with 
250 µl propidium iodide (PI) for 30 min at room temperature 
in the dark. The stained cells were analyzed by flow cytometry 
(FCM) for cell cycle analysis, and 1x106 cells were centrifuged 
at 400 x g for 10 min and resuspended in 250 µl PBS; these 
were incubated for 10 min at 37˚C with 1 µg/ml Heochst 33342. 
Following centrifugation and washing with PBS, the cells 
were resuspended in 1 ml PI and incubated for an additional 
15 min at room temperature in the dark. The stained cells were 
analyzed by FCM to assess the cell apoptosis.
Reverse transcription‑polymerase chain reaction analysis 
(RT‑PCR). Total RNA from the tumor tissue was extracted 
using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, 
USA), according to the manufacturer's instructions. RT 
was performed using the RevertAid H Minus First Strand 
cDNA Synthesis kit (Fermentas, Waltham, MA, USA), 
according to the manufacturer's instructions. The primer 
sequences used for the targeted genes were as follows: 
Sense, 5'‑TGTAAACAAACCCAGATGCAGGA‑3' and 
antisense, 5'‑CAGGTACATATCACGCGCACAG‑3' for 
EphB2; sense, 5'‑CGCCGTTGGCCAAGAACCTGG‑3' 
and antisense, 5'‑CAGCTTGTCTCCAATCTTCGG‑3' 
for Eph receptor-interacting B1 (EphrinB1); sense, 
5'‑ GA AGATCGTCGCCACCTG‑3'  and ant isense, 
5'‑GACCTCCTCCTCGCACTTCT‑3' for cyclin D1; 
sense, 5'‑CAGTACGAATGCGTGGCG‑3' and antisense, 
5'‑CTCCTCGCCGGTCTGCAC‑3' for cyclin‑dependent 
kinase 6 (CDK6); sense, 5'‑TTGCTTTACGTGGCCTGTTTC‑3' 
and antisense, 5'‑GAAGACCCTGAAGGACAGCCAT‑3' for 
Bcl‑2; and sense, 5'‑GGGAGCCAAAAGGGTCATCATCTC‑3' 
and antisense, 5'‑CCATGCCAGTGAGCTTCCCGTTC‑3' 
for GAPDH. PCR was performed with 30 cycles of 30 sec at 
94˚C, 30 sec at 58˚C and 45 sec at 72˚C. The PCR products 
were electrophoresed and the bands were visualized under 
ultraviolet radiation following staining with ethidium bromide. 
The bands were determined and semi-quantified using 
Labworks 4.6 software (UVP Products, Upland, CA, USA).
Western blot analysis. Antibodies against EphB2 and EphrinB1 
were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, 
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CA, USA), and antibodies against cyclin D1, CDK6 and Bcl‑2 
were obtained from Cell Signaling Technology, Inc. (Beverly, 
MA, USA). Proteins were extracted from the tumor tissue and 
the concentration was determined via a bicinchoninic acid 
assay kit (Pierce Biotechnology, Inc., Rockford, IL, USA). In 
total, 50 µg protein from each sample was electrophoresed at 
180 V for 1.5 h in Tris‑glycine running buffer. The proteins were 
transferred onto a nitrocellulose membrane at room temperature 
overnight and incubated with EphB2, EphrinB1, cyclin D1, 
CDK6 or Bcl-2 primary antibodies for 2 h, followed by washing 
with the second antibody for 1 h. Goat anti-β-actin polyclonal 
antibody served as an internal control and rabbit anti-goat 
secondary antibody was subsequently used. The protein expres-
sion was detected using an Enhanced Chemiluminescence Plus 
kit (Amersham Pharmacia Biotech, Amersham, UK), exposure 
to X‑ray film or under ultraviolet radiation. The bands were 
semi‑quantified using Labworks 4.6 software.
Statistical analysis. Data are presented as the mean ± standard 
error. Statistical analyses were performed by one-way analysis 
of variance, followed by the Student-Newman-Keuls test for 
multiple comparisons to compare the results of the in vivo 
experiments, FCM, and the mRNA and protein levels. P<0.05 
was considered to indicate a statistically significant difference.
Results
High expression of EphB2 indicates advantageous tumor 
growth suppression with QYHJ treatment in CFPAC‑1 cells. 
CFPAC-1, CFPAC-1 control RNAi and CFPAC-1 EphB2 RNAi 
cells with different levels of EphB2 expression were injected 
subcutaneously into female BALB/c nude mice to establish 
a tumor-bearing mouse model. The mice were divided into 
QYHJ, gemcitabine and control groups. The QYHJ group 
received a total of 200 µl liquid QYHJ twice a day by oral 
gavage, the gemcitabine group received an intraperitoneal 
injection of 120 mg/kg gemcitabine on days one, eight and 15, 
and the control group received an oral gavage of a total of 
200 µl normal saline twice a day. Tumor volume was measured 
twice a week for four weeks, and following four weeks of 
intervention, the tumor weight was measured and the tumor 
weight inhibitory rate was calculated. The results showed that 
there was no significant difference in tumor volume between 
the QYHJ and control groups following 28 days of measuring 
in the CFPAC‑1 EphB2 RNAi cells, however, a significant 
inhibition was observed in the CFPAC-1 and CFPAC-1 control 
RNAi cells (P<0.05; Fig. 1A and C). In the QYHJ group, 
tumor weight was 0.14±0.04, 0.16±0.04 and 0.40±0.10 g for 
the CFPAC-1, CFPAC-1 control RNAi and CFPAC-1 EphB2 
RNAi cells, respectively. In addition, the tumor weight inhibi-
tory rate was 31.40 and 31.33% for CFPAC-1 and CFPAC-1 
control RNAi cells, respectively, with a statistically significant 
decrease in the corresponding QYHJ group compared with the 
control group (P<0.05, P<0.01); the tumor weight inhibitory 
rate was only 18.36% in the CFPAC-1 EphB2 RNAi cells, 
with no statistically significant difference identified between 
the QYHJ and control groups (Fig. 1B and C). Different levels 
of EphB2 expression reflected the different responses to the 
  A
  B
  C
Figure 1. High expression of EphB2 indicates advantageous tumor growth suppression of QYHJ treatment in CFPAC‑1 cells. (A) No significant difference 
was identified in tumor volume following QYHJ treatment in CFPAC‑1 EphB2 RNAi cells, however, a significant inhibition was obtained in CFPAC‑1 
(P<0.05) and CFPAC‑1 control RNAi (P<0.05) cells following four weeks of intervention. (B) A statistically significant decrease was identified in tumor 
weight in CFPAC‑1 (P<0.05) and CFPAC‑1 Contol RNAi (P<0.01) cells following QYHJ treatment, however, no difference was obtained in CFPAC‑1 EphB2 
RNAi cells. (C) Tumor weight of nude mice transplanted subcutaneously with CFAPC-1 cells with different levels of EphB2 expression. Each group included 
nine to 10 nude mice. EphB2, erythropoietin-producing hepatoma cell line-B2; QYHJ, Qingyihuaji formula. *P<0.05 compared with the NS group. **P<0.01 
compared with the NS group. NS, normal saline.
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QYHJ treatment. The cells that were expressing higher levels 
of EphB2 exhibited more effective tumor growth inhibition as 
a result of the QYHJ treatment, therefore, EphB2 may function 
as an effective predictive factor for QYHJ treatment.
QYHJ suppresses tumor growth by retarding the cell cycle 
process, but not cell apoptosis in CFPAC‑1 cells. Our previous 
study showed that the overexpression of EphB2 suppressed 
tumor growth by inhibiting the cell cycle process and inducing 
cell apoptosis in CFPAC-1 cells (16). Accordingly, in the 
present study, the cell cycle and apoptosis were analyzed by 
FCM to reveal the mechanisms of the different responses to 
QYHJ treatment in CFPAC-1 cells, which were expressing 
different levels of EphB2. In the CFPAC-1 EphB2 RNAi 
cells, the proportion of cells in the G0/G1 phase was 25.34 
and 24.51% and in the S phase was 56.28 and 57.22% for the 
QYHJ and control groups, respectively (Fig. 2C and D). No 
significant change was identified in the cell cycle distribution 
following QYHJ treatment, however, QYHJ treatment blocked 
the cell cycle in the G0/G1 phase and reduced the proportion of 
cells in the S phase in CFPAC-1 and CFPAC-1 control RNAi 
cells. In the CFPAC-1 and CFPAC-1 control RNAi cells, the 
proportion of cells in the G0/G1 phase was 76.71 and 66.32% 
in the QYHJ group, respectively, and 78.47 and 67.43% in the 
control group, respectively. The QYHJ treatment resulted in a 
statistically significant increase in the G0/G1 phase popula-
tion in CFPAC-1 and CFPAC-1 control RNAi cells (P<0.05; 
Fig. 2A,B and D). An ~50% decrease in the S phase proportion 
was observed following QYHJ treatment in the CFPAC-1 and 
CFPAC-1 control RNAi cells; the proportion was decreased 
from 11.52 to 6.21% in the CFPAC‑1 cells and from 12.54 
to 6.78% in the CFPAC-1 control RNAi cells. In addition, a 
statistically significant decrease was identified in the S phase 
population in the CFPAC-1 and CFPAC-1 control RNAi cells 
following QYHJ treatment (P<0.05; Fig. 2A,B and D). The 
apoptosis rate was 11.98, 12.55 and 4.97% for the control group 
in the CFPAC-1, CFPAC-1 control RNAi and CFAC-1 EphB2 
RNAi cells, respectively, and was 12.18, 10.68 and 6.21% 
following QYHJ treatment in the corresponding cell lines 
(Fig. 3A-C). QYHJ treatment did not result in a statistically 
significant increase in the proportion of dead cells in CFPAC-1 
cells that were expressing different levels of EphB2 (Fig. 3D).
High expression of EphB2 predicts the superior response to 
QYHJ treatment via the EphrinB1‑EphB2‑CDK6 pathway 
in CFPAC‑1 cells. Our previous study found that EphB2 
induced the G0/G1 phase by blocking the downregulation 
of cyclin D1 and CDK6 in the CFPAC-1 cells (16). Previous 
studies have revealed that EphB2 emanates the intracellular 
signal by binding the transmembrane EphrinB1 ligands 
to form the Eph-EphrinB1 complex, which is required for 
EphB2 kinase activity transmission in the receptor-expressing 
cells (20,21). In addition, decreased cell growth has been 
observed in EphB2-expressing tumor cells in the presence of 
the EphrinB1/Fc ligand (22). An additional experiment was 
performed in the present study to verify the mechanism of 
the superior response to QYHJ treatment in cells, which were 
expressing higher levels of EphB2. The results showed that 
the mRNA and protein levels of EphB2 changed indistinctly, 
following QYHJ treatment, in the CFPAC-1, CFPAC-1 control 
RNAi and CFPAC-1 EphB2 RNAi cells of the subcutaneous 
tumor. QYHJ significantly increased the mRNA and protein 
  A   B
  C
  D
Figure 2. QYHJ suppresses tumor growth through inhibiting the cell cycle process. (A-C) Cell cycle was analyzed in CFPAC-1,CFPAC-1 control RNAi and 
CFPAC‑1 EphB2 RNAi cells by flow cytometry following QYHJ treatment. (D) QYHJ treatment blocked the cell cycle in the G0/G1 phase and reduced the 
S phase proportion in CFPAC‑1 and CFPAC‑1 control RNAi cells. A statistically significant increase was identified in the G0/G1 phase population (P<0.05) 
and a decrease was identified in the S phase population in CFPAC‑1 and CFPAC‑1 control RNAi cells, however, no difference was identified in the CFPAC‑1 
EphB2 RNAi cells following QYHJ treatment (P<0.05). EphB2, erythropoietin‑producing hepatoma cell line‑B2; QYHJ, Qingyihuaji formula. *P<0.05 
compared with the NS group. 
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Figure 3. Cell apoptosis is not involved in the inhibition of tumor growth following QYHJ treatment. (A‑C) Cell apoptosis was analyzed by flow cytometry 
following QYHJ treatment. (D) No statistically significant increase was identified in the apoptosis rate following QYHJ treatment in CFPAC‑1, CFPAC‑1 control 
RNAi and CFPAC‑1 EphB2 RNAi cells. EphB2, erythropoietin‑producing hepatoma cell line‑B2; QYHJ, Qingyihuaji formula; FITC, fluorescein isothiocyanate.
  A   B
  C
  D
  A   B
  C   D
Figure 4. High expression of EphB2 predicts a superior response to QYHJ treatment through the EphrinB1-EphB2-CDK6 pathway in CFPAC-1 cells. QYHJ 
resulted in an unclear change of EphB2 (A and B) mRNA and (C and D) protein level, however, a statistically significant increase was identified in the 
EphrinB1 (A and B) mRNA (P<0.05, P<0.01 and P<0.05) and (C and D) protein (P<0.05, P<0.05 and P<0.05) level following QYHJ treatment in CFPAC‑1, 
CFPAC‑1 control RNAi cells and CFPAC‑1 EphB2 RNAi cells. QYHJ also resulted in a statistically significant decrease in the CDK6 (A and B) mRNA 
(P<0.05) and (C and D) protein (P<0.05) level in CFPAC‑1 and CFPAC‑1 control RNAi cells (P<0.05), however, no change was identified in CFPAC‑1 
EphB2 RNAi cells. EphB2, erythropoietin-producing hepatoma cell line-B2; QYHJ, Qingyihuaji formula; CDK6, cyclin-dependent kinase 6; EphrinB1, Eph 
receptor-interacting B1. *P<0.05 and **P<0.01 compared with the NS group.
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level of EphrinB1 in these three cell lines and a statistically 
significant increase was identified in the EphrinB1 mRNA 
(P<0.05, P<0.01 and P<0.05) and protein (P<0.05, P<0.05 
and P<0.05) level between the corresponding QYHJ and 
control groups. Furthermore, the QYHJ treatment resulted in 
the statistically significant downregulation of CDK6 mRNA 
(P<0.05) and protein (P<0.05) levels in the CFPAC-1 and 
CFPAC-1 control RNAi cells, however, did not affect cyclin D1 
expression (Fig. 4). Cell cycle-related CDK6 and cyclin D1 
did not show a statistically significant change following 
QYHJ treatment in the CFPAC-1 EphB2 RNAi cells (Fig. 4). 
In addition, QYHJ treatment did not result in a statistically 
significant change in cell apoptosis‑related Bcl‑2 expression in 
cells that were expressing different levels of EphB2 (Fig. 4A 
and B). Consequently, the mechanism of the different cancer 
growth inhibition responses following QYHJ treatment did 
not necessarily arise as a result of the upregulation of EphB2, 
rather, it is the critical upregulation of EphrinB1 that stimu-
lates EphB2-expressing cells to inhibit cancer cell growth by 
downregulating CDK6 expression.
Discussion
Pancreatic cancer is one of the most malignant types of cancer 
worldwide. In 2012, pancreatic cancer resulted in ~85.13% of 
cancer‑related mortality in the USA. In addition, the five‑year 
survival rate was ≤5% and the median survival rate was less 
than six months (1,2). Only 20% of patients are diagnosed at 
early stage and undergo surgical treatment (23). Currently, 
chemotherapy or radiation are the best treatment options 
for >80% of advanced-stage patients, however, a number of 
these cases are found to be highly resistant to these treat-
ments (24,25). Despite the rapid advancement over the last 
decade in cancer therapy, pancreatic cancer patients benefit the 
least with regard to treatment products and survival rate due 
to the high degree of malignancy, and susceptibility to chemo-
radiation resistance. Therefore, it is imperative to identify the 
mechanism of the treatment resistance, which results in a poor 
prognosis, and to identify novel treatment strategies to prolong 
patient survival time.
Ephrin receptors are one of the largest subfamilies of 
receptor tyrosine kinases (RTKs). EphB2 is one of the 
two subgroups, which preferentially binds transmembrane 
EphrinB ligands (26-28). Previously, it was verified that 
EphB2 is a prognostic factor for several types of cancer; 
it has been associated with histological grade, stage, and 
overall and disease-free survival (7-12). Numerous studies 
have demonstrated that EphB2 preferentially acts as a 
tumor suppressor in various cancers, including colorectal 
(CRC) (13), gastric (15) and prostate (14) cancer, which is 
unlike other RTKs that are generally regarded as oncogenes. 
In CRC, the loss of EphB2 expression is observed in >50% 
patients, its downregulation accelerates the progression of 
CRC (21) and is associated with a poor prognosis (9,11,29). 
A complete loss of EphB2 expression is observed in 52.5% 
of gastric cancer and 82% of nodal metastases patients. 
Therefore, loss of EphB2 expression is significantly associated 
with advanced T stage, nodal metastasis, advanced disease 
stage and poor histological differentiation. The frequent 
deletion and decreased expression of EphB2 indicates that it 
may be a negative biomarker for gastric cancer and a poten-
tial predictor of the final outcome (15). In addition, EphB2 
has been identified as a tumor suppressor gene in prostate 
cancer (14). Despite the clear link between EphB2 and a 
number of cancers, little is known concerning the correla-
tion between EphB2 and pancreatic cancer prognosis. Our 
previous study was designed to investigate this correlation 
by eliminating EphB2 expression using lentivirus-based 
RNAi to observe the biological characteristic changes in 
pancreatic cancer CFPAC-1 cells. The results demonstrated 
that silencing EphB2 promoted cancer growth by stimu-
lating cell proliferation through a mechanism of G1/S phase 
breakthrough, which was dependent on a cyclin D1/CDK6 
cell cycle regulating signal. Similarly, EphB2 inhibition also 
reduced the apoptosis of CFPAC-1 cells by increasing Bcl-2 
expression, with EphB2 acting as a tumor suppressor in the 
cell proliferation and apoptosis in pancreatic cancer (16).
For thousands of years, TCM has been widely used for 
cancer treatment in China (30). Integrative TCM and Western 
medicine for cancer treatment has been broadly approved by 
governments and patients, including for pancreatic cancer. 
The authors of the present study have accumulated a wealth 
of experience in pancreatic cancer integrative therapy and 
obtained certain promising results. A total of 164 pancreatic 
cancer patients with liver metastases that were treated with 
chemotherapy, radiation therapy and/or QYHJ were analyzed. 
The results demonstrated an overall median survival time of 
4.7 months and a one-year survival time of 14%, with clinical 
outcomes more effective than those identified by other 
studies (31). Multivariate analysis showed that chemotherapy 
and QYHJ were protective factors (3). Notably, certain 
patients experienced long survival times when treated with 
QYHJ, however, disease continued to progress in a number 
of patients even though QYHJ treatment had been received 
in clinical practice. These differences in patient reaction to 
QYHJ treatment require investigation; there may be effective 
and ineffective populations for QYHJ treatment, therefore, 
a method to distinguish them must be identified. TCM is 
regarded as a multi-target therapy through immune altera-
tion, tumor microenvironment transforming, oncogenes or 
tumor suppressor gene regulation, and is comparable to target 
therapy in modern medicine (17,18). Previous studies have 
identified that not all patients benefit from target therapies 
since patients have their own effective population according 
to their distinctive predictors. Several types of treatment 
response predictors have been identified for target therapy, 
and gene expression predictors have been regarded as the 
most appropriate and valuable as they organically link the 
molecular biology and pharmacology (32-34). Aberrant 
activation or mutations in RTKs are responsible for tumor 
progression and development, and a number of RTKs have 
been validated as prognostic factors and therapeutic targets in 
human cancers, which are caused by activated RTKs (35‑37). 
In addition, specific RTKs have been verified as able to show a 
predictive value for target therapy (38,39). Epidermal growth 
factor receptor mutations appear to identify distinct subsets of 
patients with an increased response to gefitinib in non‑small 
cell lung carcinoma (38). In CRC, a KRAS mutation has 
previously been associated with resistance to cetuximab and 
a poorer survival in metastatic CRC patients that were treated 
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with cetuximab (39). In pancreatic cancer, histone levels are 
a survival predictor for patients who have received adjuvant 
fluorouracil; furthermore, histone modification patterns 
predicted the prognosis and the treatment response (33).
EphB2 functions as a positive prognostic factor and tumor 
suppressor in pancreatic cancer growth and our previous 
studies identified that different pancreatic cancer cell lines 
appear to exhibit different responses to QYHJ, as cells 
expressed different levels of EphB2 (6). By acting as a posi-
tive prognostic factor in pancreatic cancer, or a distinctive 
predictive factor for QYHJ treatment, partially reveals the 
mechanism of the different responses to QYHJ treatment in 
cells that express different levels of EphB2. Subsequently, a 
series of experiments were performed in the present study to 
verify this hypothesis. The results showed that tumor weight 
was 0.14±0.04, 0.16±0.04 and 0.40±0.10 g for CFPAC-1, 
CFPAC-1 control RNAi and CFPAC-1 EphB2 RNAi cells, 
respectively, and the tumor weight inhibitory rate was 31.40, 
31.33 and 18.36%, respectively. A statistically significant 
decrease was identified in tumor weight following the QYHJ 
intervention in CFPAC‑1 (P<0.05) and CFPAC‑1 control 
RNAi (P<0.01) cells. However, a statistically significant differ-
ence was predicted to appear in CFPAC-1 EphB2 RNAi cells 
following the QYHJ treatment. Previously, a high expression 
of EphB2 was found to indicate advantageous tumor growth 
suppression with QYHJ treatment in CFPAC-1 cells. This is 
comparable to the clinical results, which were identified in 
the present study, that QYHJ acts as a protective factor and 
prolongs survival time for certain patients, however, not all 
patients. Cell cycle analyses showed that QYHJ treatment 
did not change the cell cycle distribution in CFPAC-1 EphB2 
RNAi cells, however, a statistically significant increase in 
the G0/G1 phase (P<0.05), and a significant decrease in the 
S phase (P<0.05) populations was identified in CFPAC‑1 and 
CFPAC-1 control RNAi cells following QYHJ treatment. 
QYHJ treatment did not result in a statistically significant 
increase in the proportion of dead cells in CFPAC-1 cell lines 
that were expressing different levels of EphB2. Accordingly, 
a higher expression of EphB2 acted as a positive predict 
factor for QYHJ treatment, with the exception of being a 
prognostic factor in pancreatic cancer; an additional experi-
ment was performed to explore this mechanism. Previous 
studies revealed that the overexpression or loss of EphB2 
influenced the cell cycle and apoptosis (12,40,41) and that 
EphB2 emanated intracellular signals by binding EphrinB1 
ligands to form the EphB2-EphrinB1 complex (20,21,27). 
The results of the current study showed that the mRNA and 
protein level of EphB2 changed indistinctly following QYHJ 
treatment. In addition, QYHJ significantly increased the 
mRNA and protein level of EphrinB1 in CFPAC-1 cell lines 
that were expressing different levels of EphB2. The QYHJ 
treatment resulted in a statistically significant decrease in the 
S phase population, which was associated with a decrease 
in the CDK6 mRNA (P<0.05) and protein (P<0.05) levels 
in CFPAC-1 and CFPAC-1 control RNAi cells. No evident 
change was observed in the CFPAC-1 EphB2 RNAi cells. 
Furthermore, QYHJ treatment did not result in a statisti-
cally significant change in Bcl-2 expression in cells that 
were expressing different levels of EphB2. The mechanism 
of the higher expression of EphB2 acting as a predictive 
factor for QYHJ treatment arose as a result of the upregula-
tion of EphrinB1, which stimulated the EphB2-expressing 
cells to inhibit cancer cell growth by downregulating the 
CDK6 expression.
In conclusion, a high expression of EphB2 predicts a 
superior response to QYHJ treatment through a mecha-
nism that is dependent on inhibiting the cell cycle via an 
EphrinB1-EphB2-induced CDK6 decrease in CFPAC-1 cells. 
Therefore, EphB2 may act as a predictive factor for QYHJ 
treatment in pancreatic cancer CFPAC-1 cells.
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